Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that the inhibition of the
renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan
or the renin antagonist aliskiren will improve ventricular hemodynamics, as reflected by a
greater reduction in levels of N-terminal proB-type natriuretic peptide (NT-proBNP) compared
to placebo in subjects stabilized following acute coronary syndrome (ACS) who are determined
to be at high risk due to an elevated concentration of natriuretic peptides.